137 related articles for article (PubMed ID: 19524176)
1. Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment.
Onal IK; Altun B; Onal ED; Kirkpantur A; Gul Oz S; Turgan C
Eur J Intern Med; 2009 Jul; 20(4):369-72. PubMed ID: 19524176
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
3. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy.
Li-Saw-Hee FL; Edmunds E; Blann AD; Beevers DG; Lip GY
Int J Cardiol; 2000 Aug; 75(1):43-7. PubMed ID: 11054505
[TBL] [Abstract][Full Text] [Related]
5. Abnormalities of the extracellular degradation of collagen type I in essential hypertension.
Laviades C; Varo N; Fernández J; Mayor G; Gil MJ; Monreal I; Díez J
Circulation; 1998 Aug; 98(6):535-40. PubMed ID: 9714110
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
7. Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension.
Sasamura H; Kitamura Y; Nakamura M; Ryuzaki M; Saruta T
Clin Exp Hypertens; 2006 Jul; 28(5):511-20. PubMed ID: 16820347
[TBL] [Abstract][Full Text] [Related]
8. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
Ovchinnikov AG; Serbul VM; Ageev FT
Ter Arkh; 2009; 81(5):64-71. PubMed ID: 19537590
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients.
Ergul A; Portik-Dobos V; Hutchinson J; Franco J; Anstadt MP
Am J Hypertens; 2004 Sep; 17(9):775-82. PubMed ID: 15363819
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
[TBL] [Abstract][Full Text] [Related]
11. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
[TBL] [Abstract][Full Text] [Related]
13. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
14. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation.
Tayebjee MH; Nadar SK; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):770-4. PubMed ID: 15363818
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
[TBL] [Abstract][Full Text] [Related]
16. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
[TBL] [Abstract][Full Text] [Related]
17. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
18. Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats.
Cheng X; Zhou Q; Lin S; Wu R
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Oct; 35(10):1048-56. PubMed ID: 21051829
[TBL] [Abstract][Full Text] [Related]
19. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents.
Głowińska-Olszewska B; Urban M
Metabolism; 2007 Jun; 56(6):799-805. PubMed ID: 17512313
[TBL] [Abstract][Full Text] [Related]
20. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure.
López B; González A; Querejeta R; Larman M; Díez J
J Am Coll Cardiol; 2006 Jul; 48(1):89-96. PubMed ID: 16814653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
